Elevated AFP in Young Adults

Diagnostic Approach

In a young adult male with elevated AFP, the primary concern is germ cell tumor (GCT), and immediate measurement of serum hCG, testicular ultrasound, and CT imaging of the chest, abdomen, and pelvis are recommended to evaluate for testicular, retroperitoneal, or mediastinal masses 1, 2, 3
Measure serum β-hCG concurrently with AFP, as GCTs frequently produce both markers, and hCG elevation occurs in 40% of advanced nonseminomatous GCTs 1
Obtain LDH levels for risk stratification if GCT is confirmed, though LDH is nonspecific and elevated by numerous conditions including strenuous exercise, liver disease, and hemolysis 4, 5

Testicular ultrasound with a 7.5 MHz transducer is mandatory even if physical examination is normal, as occult testicular tumors can present with only marker elevation 2, 3
CT chest, abdomen, and pelvis are essential to identify retroperitoneal or mediastinal primary tumors, which occur in young men with midline masses 2, 3
Check liver function tests (ALT, AST, bilirubin) as hepatitis, cirrhosis, and other benign liver diseases commonly elevate AFP 4, 1

Cancer-associated AFP shows a consistent rising pattern, and serial measurements demonstrating progressive increases strongly suggest malignancy 4, 1
Constitutively elevated AFP (15-30 ng/mL range) may represent a chronic stable mild elevation without pathology 4, 1
Upper limit of normal: 10-15 µg/L, specifically 9 ng/mL if <40 years, 13 ng/mL if ≥40 years 1

Pure seminoma never produces AFP, and significantly elevated AFP in a patient with "pure seminoma" histology indicates mixed GCT with nonseminomatous elements 1, 6
Nonseminomatous GCT marker frequency: 10-20% in stage I, 40-60% in advanced disease produce elevated AFP 1
Hepatocellular carcinoma is a classic cause of markedly elevated AFP, though less common in young adults without cirrhosis 4, 5

If testicular mass or retroperitoneal/mediastinal mass is present, do not delay orchiectomy for marker results, and measure pre-orchiectomy markers for interpreting post-orchiectomy levels and staging 1, 6, 8
If no mass is identified on initial imaging, repeat AFP in 2-4 weeks to determine if levels are stable, rising, or falling, and consider referral to oncology for further evaluation if rising pattern is observed 4, 1
Measure AFP, hCG, LDH before each treatment cycle if GCT is diagnosed, and every 2-4 months in the first year, every 3-4 months in the second year, and annually for at least 10 years for post-treatment surveillance 7, 5, 8